Literature DB >> 27980013

Histopathological Classification and Renal Outcome in Patients with Antineutrophil Cytoplasmic Antibodies-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis.

Yong-Xi Chen1,2, Jing Xu1,2, Xiao-Xia Pan1,2, Ping-Yan Shen1,2, Xiao Li1,2, Hong Ren1,2, Xiao-Nong Chen1,2, Li-Yan Ni1,2, Wen Zhang3,4, Nan Chen1,2.   

Abstract

OBJECTIVE: Renal vasculitis is one of the most common manifestations of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) and renal histology is a key predictor of the outcome. A new histopathologic classification was proposed and validated, but the results are still debated.
METHODS: We performed a retrospective analysis to validate the histopathologic classification and performed a metaanalysis to evaluate its predictive value. There were 186 patients with ANCA-associated renal vasculitis diagnosed at Ruijin Hospital who were enrolled in the retrospective study. The metaanalysis considered the data for 1601 patients.
RESULTS: In our retrospective study, patients with focal class had the best renal outcome while patients with mixed class had the worst (p < 0.001). Metaanalysis showed that patients with focal class had better renal outcome than did those with crescentic class [risk ratio (RR) 0.23, 95% CI 0.16-0.34, p < 0.00001], with no evidence of heterogeneity (I2 = 0%, p = 0.96). Patients with crescentic class had better renal outcome than did those with sclerotic class (RR 0.52, 95% CI 0.41-0.64, p < 0.00001), with no evidence of heterogeneity (I2 = 2%, p = 0.43). We did not find statistical significance regarding renal outcome between mixed and crescentic classes (RR 1.14, 95% CI 0.91-1.43, p = 0.27), with no evidence of heterogeneity (I2 = 23%, p = 0.19). The retrospective study showed that lung and upper respiratory tract involvement were the most common extrarenal manifestations.
CONCLUSION: We demonstrated the clinical utility of histopathologic classification in determining renal outcome in patients with AAV. Metaanalysis showed that patients with focal class had the best outcome while sclerotic class had the worst.

Entities:  

Keywords:  ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; HISTOPATHOLOGIC CLASSIFICATION; METAANALYSIS; OUTCOME; RENAL VASCULITIS

Mesh:

Substances:

Year:  2016        PMID: 27980013     DOI: 10.3899/jrheum.160866

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  27 in total

1.  Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study.

Authors:  L García; C E Pena; R Águila Maldonado; C Costi; M Mamberti; E Martins; M A García
Journal:  Clin Rheumatol       Date:  2019-06-20       Impact factor: 2.980

2.  Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis.

Authors:  Li Huang; Chanjuan Shen; Yong Zhong; Joshua D Ooi; Ya-Ou Zhou; Jin-Biao Chen; Ting Wu; Ting Meng; Zhou Xiao; Wei Lin; Xiang Ao; Xiangcheng Xiao; Qiaoling Zhou; Ping Xiao
Journal:  Clin Exp Med       Date:  2020-02-20       Impact factor: 3.984

3.  A Case of ANCA-Associated Vasculitis.

Authors:  Jonathan J Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-05       Impact factor: 8.237

4.  Keeping Up with the Times: Prognostic Tools in ANCA-Associated Glomerulonephritis.

Authors:  Silke R Brix; Duvuru Geetha
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-28       Impact factor: 8.237

5.  Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement.

Authors:  H Marco; J Draibe; J Villacorta; L F Quintana; N Martin; R Garcia-Osuna; C Cabre; M A Martín-Gómez; A Balius; A Saurina; M Picazo; I Gich-Saladich; M Navarro-Díaz; M Praga; T Cavero; J Ballarin; M M Díaz-Encarnación
Journal:  Clin Rheumatol       Date:  2018-03-09       Impact factor: 2.980

6.  Clinical and histopathological prognostic factors affecting the renal outcomes in childhood ANCA-associated vasculitis.

Authors:  Gül Özçelik; Hafize Emine Sönmez; Sezgin Şahin; Ayşim Özağarı; Meral Torun Bayram; Rümeysa Yasemin Çiçek; Evrim Kargın Çakıcı; Elif Çomak; Kenan Barut; Nihal Şahin; Sevcan Bakkaloğlu; İbrahim Gökçe; Ali Düzova; Yelda Bilginer; Ceyhun Açarı; Engin Melek; Beltinge Demircioğlu Kılıç; Semanur Özdel; Amra Adroviç; Özgür Kasapçopur; Erbil Ünsal; Harika Alpay; Diclehan Orhan; Rezan Topaloğlu; Ruhan Düşünsel; Seza Özen
Journal:  Pediatr Nephrol       Date:  2019-01-04       Impact factor: 3.714

Review 7.  An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a Bayesian network meta-analysis.

Authors:  Shanshan Huang; Qing Shen; Ruoqing Yang; Heng Lai; Jing Zhang
Journal:  Int Urol Nephrol       Date:  2018-07-25       Impact factor: 2.370

8.  Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort.

Authors:  Alvise Berti; Emilie Cornec-Le Gall; Divi Cornec; Marta Casal Moura; Eric L Matteson; Cynthia S Crowson; Aishwarya Ravindran; Sanjeev Sethi; Fernando C Fervenza; Ulrich Specks
Journal:  Nephrol Dial Transplant       Date:  2019-09-01       Impact factor: 5.992

9.  Clinical and pathological analysis of 101 cases of ANCA-associated vasculitic kidney injury.

Authors:  Shumiao Yang; Yafang Liu; Qingfei Xiao; Chenhao Li; Hongyue Wang
Journal:  Int Urol Nephrol       Date:  2021-03-05       Impact factor: 2.370

Review 10.  Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis.

Authors:  Emma E van Daalen; Maria A C Wester Trejo; Arda Göçeroğlu; Franco Ferrario; Kensuke Joh; Laure-Hélène Noël; Yayoi Ogawa; Suzanne Wilhelmus; Miriam J Ball; Eva Honsova; Zdenka Hruskova; Renate Kain; Tomoyoshi Kimura; Marek Kollar; Andreas Kronbichler; Kristine Lindhard; Xavier Puéchal; Steven Salvatore; Wladimir Szpirt; Hideki Takizawa; Vladimir Tesar; Annelies E Berden; Olaf M Dekkers; E Christiaan Hagen; Jan Oosting; Chinar Rahmattulla; Ron Wolterbeek; Willem Jan Bos; Jan A Bruijn; Ingeborg M Bajema
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-28       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.